Table S1. Association between clinicopathological characteristics and EGFR mutation status in patients with advanced LUAD.
| Patient characteristics | Driver-gene negative (n=24) | EGFR positive (n=69) | P value |
|---|---|---|---|
| Age (year), n (%) | 0.219 | ||
| <60 | 11 (45.8) | 22 (31.9) | |
| ≥60 | 13 (54.2) | 47 (68.1) | |
| Gender, n (%) | 0.001* | ||
| Female | 4 (16.7) | 38 (55.1) | |
| Male | 20 (83.3) | 31 (44.9) | |
| Smoking pack year, mean ± SD | 30.64±33.71 | 13.43±26.93 | 0.090 |
| Smoking status, n (%) | 0.000* | ||
| Non-smokers | 6 (25.0) | 48 (69.6) | |
| Current/former smokers | 18 (75.0) | 21 (30.4) | |
| AJCC stage, n (%) | 0.685 | ||
| III | 5 (20.8) | 10 (14.5) | |
| VI | 19 (79.2) | 59 (85.5) | |
| T stage, n (%) | 0.839 | ||
| T1 | 5 (20.8) | 10 (14.5) | |
| T2 | 5 (20.8) | 17 (24.6) | |
| T3 | 4 (16.7) | 9 (13.0) | |
| T4 | 10 (41.7) | 33 (47.8) | |
| N stage, n (%) | 0.441 | ||
| N0 | 1 (4.2) | 9 (13.0) | |
| N1 | 1 (4.2) | 6 (8.7) | |
| N2 | 9 (37.5) | 25 (36.2) | |
| N3 | 13 (54.2) | 29 (42.0) | |
| PD-L1 TPS, n (%) | |||
| ≥1% | 15 (62.5) | 23 (33.3) | 0.700 |
| ≥50% | 12 (50.0) | 19 (29.7) | 0.258 |
*, P<0.05 was considered as statistically significant. LUAD, lung adenocarcinomas; AJCC, American Joint Committee on Cancer; PD-L1 TPS, tumor proportion scores of PD-L1.